NCT06285097 - A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 8, 2024

Primary Completion Date

January 3, 2025

Study Completion Date

February 13, 2025

Conditions

NeoplasmsNon-small-cell Lung CancerMelanomaSquamous Cell Carcinoma of the Head and NeckRenal Cell CarcinomaUrothelial CarcinomaColorectal CarcinomaOvarian Carcinoma

Interventions

DRUG

PF-07820435

immune agonist

BIOLOGICAL

Sasanlimab

A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/L2

Trial Locations (10)

34232

Florida Cancer Specialists Sarasota Drug Development Unit, Sarasota

37203

Sarah Cannon Research Institute - Pharmacy, Nashville

SCRI Oncology Partners, Nashville

Tristar Centennial Medical Center, Nashville

49503

Corewell Health (reference non-engagement letter), Grand Rapids

49546

START Midwest, Grand Rapids

277-8577

National Cancer Center Hospital East, Kashiwa

135-8550

The Cancer Institute Hospital of JFCR, Koto

00935

Hospital Oncologico Dr. Isaac Gonzalez-Martinez, Rio Piedras

Pan American Center for Oncology Trials, LLC, Rio Piedras